Early antibody response in health-care professionals after two doses of SARS-CoV-2 mRNA vaccine (BNT162b2).

ABSTRACT:

Objectives

Data on the immune response after two doses of BNT162b2 are so far limited. Previously infected individuals were excluded from pivotal clinical trials and the optimum dose regimen in this population has not been clearly studied. The CRO-VAX HCP study aims to investigate the early antibody response in a population of health-care professionals having received two doses of the BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine.

Methods

The CRO-VAX HCP study is a multicentre, prospective, interventional study conducted in several sites in Belgium. The study included 231 health-care professional volunteers who received the two-dose regimen of the BNT162b2 mRNA COVID-19 vaccine. Of these, 73 were previously infected by severe acute respiratory syndrome coronaviru

SUBMITTER: Favresse J 

PROVIDER: S-EPMC8106520 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature